Overall survival (OS) of 106 acute erythroid leukemic patients by treatment modalities. The 21 patients who underwent allogeneic bone marrow transplantation (BMT) had a superior OS (median, 23 months) compared with 52 patients who received induction chemotherapy without BMT (median, 9 months; P = .015) as well as 33 patients who did not receive high-intensity chemotherapy (median OS, 4 months; P = .002). There was no difference in OS between patients receiving induction versus those who did not receive high-intensity chemotherapy (P = .10).